Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]fm-PBR28-d2
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
`[18F]fm-PBR28-d2` (deuterium-substituted `[18F]`fluoromethyl-PBR28) is a radiolabeled small molecule positron emission tomography (PET) and Cerenkov luminescence imaging (CLI) tracer targeting the 18 kDa translocator protein (TSPO). Developed by researchers at Seoul National University, it is a deuterated analog of `[18F]`fluoromethyl-PBR28 designed to improve in vivo stability against defluorination, thereby reducing bone uptake (e.g., in the skull and femur) and enhancing the target-to-background ratio. It is primarily investigated in preclinical research for imaging neuroinflammation (such as in stroke models) and visualizing interscapular brown adipose tissue (iBAT) activity, where it has demonstrated superior sensitivity and correlation with uncoupling protein 1 (UCP1) expression compared to `[18F]`FDG.
- Other names
- [18F]fluoromethyl-PBR28-d2[18F]fmPBR28-d2deuterium-substituted [18F]fluoromethyl-PBR28fm-PBR28-d2fm-PBR-28-d2fm-PBR 28-d2fmPBR28-d2fmPBR-28-d2fmPBR 28-d2fluoromethyl-PBR28-d2fluoromethyl-PBR-28-d2fluoromethyl-PBR 28-d2
02
Targets
TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on [18F]fm-PBR28-d2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]fm-PBR28-d2.